| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | SJ-172550 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0087 | 0.8 |
| mRNA | austocystin d | CTRPv2 | pan-cancer | AAC | 0.0098 | 0.8 |